Values as of: 2024-11-09
COMMON STOCK | Biotechnology |
Last Closing
USD 173.54Change
0.00 (0.00)%Market Cap
USD 83.49BVolume
N/AAnalyst Target
N/AVerdict
Verdict
Currency: EUR
Country : Germany
| Symbol | Name | Price(Change) | Market Cap |
|---|---|---|---|
| RGO:F | Regeneron Pharmaceuticals Inc |
-5.60 (-0.72%) |
USD 84.33B |
| CSJA:F | CSL LTD SPON.ADR 2 |
+1.50 (+1.73%) |
USD 82.40B |
| UNC0:F | UCB S.A. UNSP.ADR 1/2 |
-4.00 (-4.26%) |
USD 34.23B |
| 1AE:F | Argen-X |
-14.40 (-2.57%) |
USD 33.52B |
| 1AEA:F | argenx SE |
-5.00 (-0.91%) |
USD 33.15B |
| DUL:F | Alnylam Pharmaceuticals Inc |
-2.50 (-0.96%) |
USD 32.23B |
| 22UA:F | BioNTech SE |
-2.80 (-2.72%) |
USD 24.86B |
| 49BA:F | BeiGene Ltd |
-6.00 (-3.06%) |
USD 22.99B |
| 49B:F | BeiGene Ltd. |
-0.50 (-3.40%) |
USD 21.35B |
| 0QF:F | Moderna Inc |
+0.65 (+1.62%) |
USD 16.69B |
N/A
| Market Performance vs. Industry/Classification (Biotechnology) | Market Performance vs. Exchange | ||||||
| Value | Sector Median | Percentile Rank | Grade | Market Median | Percentile Rank | Grade | |
| YTD | |||||||
| Capital Gain | -1.23% | 56% | F | 46% | F | ||
| Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
| Total Return | -1.23% | 57% | F | 46% | F | ||
| Trailing 12 Months | |||||||
| Capital Gain | 16.08% | 59% | D- | 58% | F | ||
| Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
| Total Return | 16.08% | 60% | D- | 58% | F | ||
| Trailing 5 Years | |||||||
| Capital Gain | 4.03% | 55% | F | 50% | F | ||
| Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
| Total Return | 4.03% | 55% | F | 50% | F | ||
| Average Annual (5 Year Horizon) | |||||||
| Capital Gain | 0.13% | 61% | D- | 43% | F | ||
| Dividend Return | 0.92% | 62% | D | 40% | F | ||
| Total Return | 0.80% | 43% | F | 30% | F | ||
| Risk Return Profile | |||||||
| Volatility (Standard Deviation) | 11.09% | 97% | N/A | 87% | B+ | ||
| Risk Adjusted Return | 8.34% | 65% | D | 41% | F | ||
| Market Capitalization | 83.49B | 100% | F | 98% | N/A | ||
| Target Price Action | Rating Action | Analyst | Rating | Price | Date |
|---|
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.
The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.
The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
The company had positive total free cash flow in the most recent four quarters.
The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.
The stock is trading high compared to its peers median on a price to book value basis.
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
The company has under performed its peers on annual average total returns in the past 5 years.
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
This stock has shown below median revenue growth in the previous 5 years compared to its sector
